STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- Extraordinary
General Meeting of Immunovia AB (publ), Corp. Reg. No. 556730-4299
was held at The Spark in Medicon Village, Scheeletorget 1,
Lund, Sweden, on September 23, 2020. A summary of the decisions
taken is presented below.
Election of new Board member
The Meeting resolved on the election of the current, but
outgoing, CEO Mats Grahn as a new
member of the Board of Directors.
Update to the resolution on the remuneration of Board and
Committee members
The Meeting resolved to update the Annual General Meeting
decision concerning remuneration of Board members according to
which each of the Board members will receive SEK 240,000, and the Chairman of the Board
SEK 550,000. The Chairman of the
Audit Committee and of the Remuneration Committee will each receive
SEK 50,000 and other members of the
aforementioned Committees SEK
30,000.
Resolution on the incentive scheme for key persons
The Meeting resolved on the issue, with a deviation from the
shareholders' preferential rights, of not more than 450,000
warrants within the framework of an incentive scheme for key
persons in the company, and authorized the Board to introduce an
alternative cash-based incentive scheme for key persons in
countries where the allocation of warrants is not appropriate.
Immunovia AB (publ)
Board of Directors
Queries may be addressed to:
Mats Grahn, CEO
E-mail: mats.grahn@immunovia.com
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/summary-from-the-extraordinary-general-meeting-of-immunovia,c3201609
The following files are available for download:
https://mb.cision.com/Main/13121/3201609/1309936.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/summary-from-the-extraordinary-general-meeting-of-immunovia-301136794.html
SOURCE Immunovia AB